Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial

OBJECTIVES: The Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) trial suggested a higher risk of cardiovascular (CV) death from febuxostat than from allopurinol. However, a significant number of patients died after discontinuation of febuxostat or allopurinol. We inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghang, Byeong-zu, Lee, Ji Sung, Choi, Jihye, Kim, Jinseok, Yoo, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Crystal Arthropathies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226988/
https://www.ncbi.nlm.nih.gov/pubmed/35732345
http://dx.doi.org/10.1136/rmdopen-2021-001944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226988/
https://www.ncbi.nlm.nih.gov/pubmed/35732345
http://dx.doi.org/10.1136/rmdopen-2021-001944

Ejemplares similares